FDA authorizes novel combination treatment for specific prostate cancer type

The Food and Drug Administration (FDA) has approved a new combination therapy, talazoparib with enzalutamide, for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that carries homologous recombination repair (HRR) gene mutations. This decision expands available treatment options for patients with this particular genetic profile, offering a new therapeutic approach.